67 terminated. 67 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 67 | Terminated 67 |
| Phase 2 | 5 | Terminated 5 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Terminated | Regeneron Pharmaceuticals | 24 | 2026-01-10 | 2026-09-01 |
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT) Dupilumab, Placebo, Intranasal Corticosteroid Sprays (INCS) - Allergic Fungal Rhinosinusitis | Phase 3 | Terminated | Emory University | 5 | 2023-10-26 | 2025-05-08 |
| INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions Salbutamol, Placebo - IgE-mediated Abdominal Pain | Phase 3 | Terminated | Philippe Bégin | 24 | 2023-07-01 | 2025-05-21 |
| A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Rocatinlimab, Placebo - Atopic Dermatitis | Phase 3 | Terminated | Amgen | 2621 | 2023-05-31 | 2026-07-16 |
| Long-term Extension Study of Ligelizumab in Food Allergy Ligelizumab 120 mg, Ligelizumab 240 mg - Food Allergy | Phase 3 | Terminated | Novartis Pharmaceuticals | 163 | 2023-04-27 | 2026-01-13 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified | Phase 2 / Phase 3 | Terminated | Pfizer | 58 | 2023-01-18 | 2025-05-08 |
| Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream - Pruritus, Atopic Dermatitis | Phase 3 | Terminated | Cara Therapeutics, Inc. | 287 | 2022-08-16 | 2024-02-22 |
| Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Tezepelumab, Placebo - Asthma | Phase 3 | Terminated | AstraZeneca | 125 | 2022-08-09 | 2026-06-18 |
| Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation Application of Tralokinumab - Atopic Dermatitis | Phase 2 / Phase 3 | Terminated | University of Zurich | 24 | 2022-06-15 | 2026-02-06 |
| Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy ligelizumab, Placebo - Allergy, Peanut | Phase 3 | Terminated | Novartis Pharmaceuticals | 211 | 2021-12-07 | 2025-04-29 |
| AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department Azithromycin, Placebo - Asthma, Wheezing | Phase 3 | Terminated | University of Arizona | 840 | 2021-11-22 | 2026-06-23 |
| Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines Ligelizumab, Placebo - Chronic Inducible Urticaria | Phase 3 | Terminated | Novartis Pharmaceuticals | 39 | 2021-11-16 | 2024-06-18 |
| A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat REGN1908-1909, Matching Placebo - Allergic Rhinitis Due to Cat Allergy | Phase 3 | Terminated | Regeneron Pharmaceuticals | 446 | 2021-07-30 | 2024-06-11 |
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000) - Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis | Phase 3 | Terminated | Inmunotek S.L. | 18 | 2021-04-30 | 2023-12-19 |
| A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. Benralizumab, Placebo - Bullous Pemphigoid | Phase 3 | Terminated | AstraZeneca | 67 | 2021-03-31 | 2024-11-29 |
| A Study of Benralizumab in Patients With Eosinophilic Esophagitis Benralizumab, Matching placebo - Eosinophilic Esophagitis | Phase 3 | Terminated | AstraZeneca | 211 | 2020-09-22 | 2023-11-18 |
| A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis Crisaborole 2% - Atopic Dermatitis | Phase 3 | Terminated | Pfizer | 40 | 2020-09-14 | 2021-08-12 |
Showing 20 of 67. Sign in to see all of them.
Asthma (34) · Dermatitis, Atopic (9) · Eczema (6) · Pruritus (4) · Pulmonary Eosinophilia (4) · Conjunctivitis, Allergic (3) · Diabetes Mellitus, Type 1 (3) · Diabetes Mellitus, Type 2 (3) · Food Hypersensitivity (3) · Peanut Hypersensitivity (3) · Rhinitis, Allergic (3) · Urticaria (3) · Angioedemas, Hereditary (2) · Bronchial Diseases (2)
Immune System Diseases (66) · Hypersensitivity, Immediate (63) · Respiratory Tract Diseases (39) · Respiratory Hypersensitivity (38) · Lung Diseases (34) · Bronchial Diseases (32) · Lung Diseases, Obstructive (32) · Skin Diseases (18) · Skin and Connective Tissue Diseases (18) · Pathological Conditions, Signs and Symptoms (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (12) · Dermatitis (10) · Skin Diseases, Genetic (10)
Albuterol (6) · benralizumab (4) · ligelizumab (4) · Fluticasone (2) · fevipiprant (2) · rupatadine (2) · 68Ga-DOTANOC (1) · Allergens (1) · Azithromycin (1) · Beclomethasone (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Complement C1 Inhibitor Protein (1) · Dexamethasone (1) · Formoterol Fumarate (1)
AstraZeneca (7) · Novartis Pharmaceuticals (7) · Amphastar Pharmaceuticals, Inc. (3) · Areteia Therapeutics (3) · Boehringer Ingelheim (2) · Mannkind Corporation (2) · Pfizer (2) · Regeneron Pharmaceuticals (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · ALK-Abelló A/S (1) · Aimmune Therapeutics, Inc. (1) · Allergan (1) · Amgen (1) · Amneal Ireland Limited (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (43) · Spain (18) · France (17) · Germany (17) · Canada (16) · Poland (16) · Japan (13) · Argentina (11) · Czechia (11) · United Kingdom (11) · Australia (10) · Brazil (10) · Italy (10) · Russia (10) · Belgium (9)
Ana Isabel Tabar Purroy, MD; PhD (1) · Brandon S Lu, MD, MS (1) · Carlos Barcina, MD (1) · Charlie Casper, PhD (1) · Don C Rockey, MD (1)
PMID 39393433, PMID 21988742, PMID 24906637, PMID 29536781, PMID 30552284, PMID 33710614, PMID 33826132, PMID 34895218, PMID 35846226, PMID 36749121, PMID 38814736, PMID 38924732, PMID 39777591, PMID 39954913, PMID 42149992, PMID 42150582
2023 (4), 2018 (3), 2016 (2), 2019 (2), 2005 (1), 2008 (1), 2015 (1), 2017 (1)